Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • duonglinhnam
    Junior Member
    • Jul 2018
    • 1

    #1

    Assembly vs mapping results

    Hi guys, I performed RNA-seq analysis of bacterial transcriptome in four different stressed conditions, mapping the reads on its own genome available in NCBI. Then I used FeatureCounts for reads counting and finally I performed differential analysis with NOISeq R package, because of the absence of replicates.
    Before that, my tutor submitted the analysis to a famous company requiring a de novo assembly (they used the trinity pipeline for assembly and differential analysis).
    I used the same fastq files, and finally I found a larger number of DE genes, but my results are the opposite of company's results. How is it possible? I know that mapping is better than assembly when a reference genome is available and above all I know that the trinity pipeline have some problems for differential analysis, because it uses DESeq or edgeR after quantification by RSEM.
    What do you think about?
  • GenoMax
    Senior Member
    • Feb 2008
    • 7142

    #2
    This question is difficult to answer without access to data. Why did the company used trinity when you have bacterial genomes and don't expect any splicing. Trinity only assembles transcripts and does not do any diff analysis. Did you not tell the company about the reference genomes available when you asked them to do sequencing?

    Were you mapping reads to a very close genome at NCBI? Bacterial genomes can vary a lot even for type strains for what is in your lab and reference at NCBI.

    Comment

    • Bukowski
      Senior Member
      • Jan 2010
      • 388

      #3
      What do you mean by 'opposite'?

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
        by SEQadmin2



        Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

        Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
        ...
        Today, 09:55 AM
      • SEQadmin2
        New Genomics Technologies Take Aim at Long-Standing Limits
        by SEQadmin2


        Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

        We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
        ...
        09-28-2026, 10:25 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, Today, 05:39 AM
      0 responses
      9 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, Yesterday, 09:56 AM
      0 responses
      11 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-09-2026, 11:14 AM
      0 responses
      25 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 09-29-2026, 09:51 AM
      0 responses
      77 views
      0 reactions
      Last Post SEQadmin2  
      Working...